First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™) for the treatment of myotonic dystrophy type 1 (DM1) Avidity Bioscience, a californian biotech company committed to delivering a new class of RNA therapeutics, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with its lead…..